Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2022-08-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于2022年7月份生猪销售简报
Regulatory Filings Classification · 95% confidence The document is a sales brief for July 2022 from Tian Kang Biological Co., Ltd., detailing sales volume and revenue of live pigs for that month and cumulative sales for the year to date. It includes a risk warning and clarifies that the data is unaudited and for reference only. The document is short (923 characters) and does not contain comprehensive financial statements or detailed analysis. It is a periodic sales update rather than a full financial report or earnings release. It is not an announcement of a report publication but a standalone brief sales update. Given the nature of the content, it fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement and update that does not fit other specific categories like Earnings Release or Interim Report.
2022-08-09 Chinese
2022年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 fourth extraordinary general meeting of shareholders of Tian Kang Biological Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and decisions made by shareholders, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements. The document length is 3333 characters, which is sufficient to contain substantive voting results rather than just a brief announcement or a report publication notice. Therefore, the appropriate classification is DVA.
2022-08-05 Chinese
新疆星河律师事务所关于天康生物股份有限公司2022年第四次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2022 fourth extraordinary general meeting of shareholders of Tian Kang Bio. It details the legality of the meeting's notice, attendance, voting procedures, and results. It is not a report of financial results, audit, or management discussion, but a legal opinion on the meeting process and voting outcomes. This type of document is typically associated with the declaration of voting results or voting rights announcements following a shareholder meeting. The document length is 3513 characters, which is relatively short but contains substantive content about voting results and legality, not just an announcement of a report publication. Therefore, the best fitting category is Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-08-05 Chinese
关于不提前赎回天康转债的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Tian Kang Bio Co., Ltd. regarding the decision not to exercise the early redemption right of its convertible bonds (referred to as 'Tian Kang Convertible Bonds'). It details the bond issuance background, the conditional redemption clauses, the recent triggering of these clauses, and the board's resolution not to redeem early. The document includes meeting resolutions and disclosures about insider trading related to the bonds. It is a regulatory announcement about bond redemption decisions and related corporate actions, not a financial report, earnings release, or detailed management discussion. The document length is about 2,678 characters, which is relatively short and focused on a specific corporate action. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as bond redemption decisions.
2022-08-03 Chinese
第七届董事会第三十次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Tian Kang Biological Co., Ltd. It details the decision not to redeem convertible bonds early, includes voting results, and references compliance with company law and articles of association. The document is short (910 characters) and does not contain financial statements or detailed financial data. It is an announcement of a board decision rather than a full management report or financial report. Therefore, it fits best under Board/Management Information (MANG).
2022-08-03 Chinese
关于天康转债可能满足赎回条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Tian Kang Biological Co., Ltd. regarding the potential fulfillment of the conditional redemption clause for its convertible bonds (referred to as 'Tian Kang Convertible Bonds'). It details the bond issuance background, the conditions under which the bonds may be redeemed early, recent stock price performance relevant to these conditions, and the company's intention to monitor and disclose further developments. The document does not contain financial statements, quarterly or annual results, nor is it a transcript or presentation. It is a regulatory announcement about a potential capital/financing event (bond redemption). Therefore, it fits best under Capital/Financing Update (CAP). The document length is moderate and contains detailed information about bond terms and redemption conditions, not just a brief notice or report publication announcement.
2022-07-27 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.